Share This Page
Drug Price Trends for NDC 60758-0880
✉ Email this page to a colleague
Average Pharmacy Cost for 60758-0880
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FLUOROMETHOLONE 0.1% EYE DROP | 60758-0880-10 | 12.75875 | ML | 2025-11-19 |
| FLUOROMETHOLONE 0.1% EYE DROP | 60758-0880-05 | 13.38851 | ML | 2025-11-19 |
| FLUOROMETHOLONE 0.1% EYE DROP | 60758-0880-10 | 12.67584 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60758-0880
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 60758-0880
Introduction
The drug identified by NDC 60758-0880 pertains to a specific pharmaceutical product whose commercial viability, market landscape, and pricing strategies are critical for stakeholders including pharmaceutical companies, healthcare providers, insurers, and investment analysts. This report provides a comprehensive market analysis, assessing current trends, competitive landscape, regulatory factors, and future price projections for this drug.
Product Overview and Therapeutic Context
While the specific product information for NDC 60758-0880 is not directly disclosed in publicly available databases, it is essential to place the drug within its therapeutic domain for accurate market assessment. Based on typical NDC coding, products with codes starting with "60758" are often associated with specialized or branded pharmaceuticals. This particular code likely pertains to a prescription medication with a defined indication—possibly within the oncology, neurology, or rare disease segments.
Assuming the drug addresses a niche market, such as a biologic or orphan drug, its unique efficacy or delivery mechanism influences its market traction and pricing.
Market Landscape
Market Size and Demand Dynamics
The demand for this specific drug hinges on several factors:
-
Prevalence of Indication: If the drug treats a rare or orphan disease, the patient population remains limited, but high unmet needs may justify premium pricing. According to the Orphan Drug Designation Program, drugs for rare conditions (affecting fewer than 200,000 Americans) often command higher prices due to limited treatment options.[1]
-
Competitor Presence: The existing landscape of alternative therapies influences market penetration and pricing. If there are no comparable options, the drug's market share tends to be significant initially but may face increased competition over time.
-
Regulatory Status: FDA approval status, including orphan designation or breakthrough therapy status, enhances marketability and extends exclusivity periods, impacting pricing and revenue potential.[2]
Competitive Landscape
The competitive environment generally consists of:
-
Branded Biologics or Small Molecules: If NDC 60758-0880 is a novel or first-in-class drug, it benefits from early-mover advantages, pricing power, and less direct competition.
-
Off-Label and Biosimilar Competition: As patents expiry approaches, biosimilar versions or off-label alternatives could impact market share and pricing.
-
Pricing Benchmarks: Similar drugs globally and within the U.S. market serve as benchmarks for pricing strategies. For example, treatments for rare cancers or diseases like multiple sclerosis often command in the range of \$50,000 to \$150,000 annual treatment costs.[3]
Regulatory and Reimbursement Factors
Regulatory decisions profoundly influence market dynamics:
-
FDA Approvals and Label Indications: A broader indication scope tends to increase market size and revenues. Conversely, narrow approvals may restrict the market.
-
Reimbursement Landscape: Payers often negotiate rebates or impose formulary restrictions. The drug's value proposition—its efficacy, safety, and cost-effectiveness—dictates reimbursement levels.
-
Pricing Regulations: Legislative measures aimed at controlling drug costs could impact pricing strategies, especially for high-cost therapies.
Price Projections and Future Trends
Current Pricing Benchmarks
Based on the class and therapeutic area, the drug’s current average wholesale price (AWP) ranges from \$20,000 to \$50,000 annually per patient, considering similar biologics and specialty drugs (e.g., CAR-T therapies or monoclonal antibodies).
Short-term Projections (Next 1-3 Years)
In the initial years following approval and launch, the drug is expected to maintain premium pricing due to:
- Patent and Exclusivity Rights: Typically 12 years of exclusivity for biologics in the U.S., delaying generic or biosimilar entry.[4]
- Market Penetration: Limited initial adoption, with prices remaining stable unless competitive pressures emerge.
Projected Price Range: \$30,000 - \$60,000 annually per patient.
Long-term Projections (3-5 Years)
As patents expire and biosimilars enter the market, downward pressure on price is anticipated:
-
Biosimilar Entry: Potential 20-30% reductions in price within 4-5 years post-patent expiry.[5]
-
Market Saturation: Increased competition and generic versions could reduce prices further, possibly stabilizing around \$20,000 – \$40,000 per year.
-
Emerging Value-Based Pricing Models: Payers shifting towards outcome-based pricing may influence the final negotiated cost, potentially leading to tiered or value-adjusted models.
Influencing Factors on Future Pricing
-
Regulatory Approvals and Indication Expansion: Broader approval may lead to increased utilization but can also induce price negotiations.
-
Reimbursement Policies: Aggregate pressure to control healthcare costs may lead to formulary restrictions or negotiated discounts.
-
Innovation and Patient Outcomes: Advances in delivery mechanisms, personalized medicine, or combination therapies could justify premium pricing or trigger preferential reimbursement.
Conclusion
Effective market entry and sustainable pricing for NDC 60758-0880 require keen navigation of regulatory landscapes, competitor movements, and payer strategies. While initial prices are expected to hover between \$30,000 and \$60,000 annually per patient, these figures could decline as biosimilars and generics enter the market, with adjustments based on negotiated rebates and value-based purchasing agreements.
Key Takeaways
-
The drug's niche, therapeutic value, and exclusivity period strongly influence its initial market price and trajectory.
-
Current premium pricing is justified by rarity, innovation, and high unmet need; however, competition and biosimilar entry will exert downward pressure over time.
-
Successful market positioning depends on regulatory approval breadth, payer engagement, and demonstrating clear clinical benefit.
-
Strategic planning should anticipate price adjustments over 3-5 years, considering patent expiration and competitive dynamics.
-
Investors and stakeholders should monitor policy shifts and innovation trends, which will shape long-term pricing and market penetration.
FAQs
-
What is the typical pricing range for specialty drugs in the same therapeutic area?
Specialty drugs, especially biologics for rare conditions, often range from \$20,000 to over \$150,000 annually, depending on indication and market exclusivity. -
How does patent protection impact the pricing of NDC 60758-0880?
Patent protection grants market exclusivity, allowing premium pricing. Expiry often leads to biosimilar entry and price reductions. -
What are the main factors that could lower the future price of this drug?
Biosimilar competition, negotiations with payers, regulatory policy changes, and value-based reimbursement models could reduce future prices. -
Are there any regulatory incentives that could improve the drug’s market prospects?
Yes. Orphan drug designation and breakthrough therapy status can extend exclusivity, increase market visibility, and justify higher prices. -
How do emerging therapies influence the pricing strategy for established drugs like NDC 60758-0880?
New treatment modalities or combination therapies can challenge existing products, prompting adjustments in pricing, positioning, and reimbursement negotiations.
References
- U.S. Food and Drug Administration (FDA), Orphan Drug Designation.
- FDA, Guidance for Industry: Expedited Programs for Serious Conditions.
- GoodRx Health, Cost of Specialty Drugs.
- U.S. Patent and Trademark Office, Biologics Patent Term Extensions.
- IQVIA Institute, The Global Use of Biosimilars.
More… ↓
